Delivery Order SPE2DB22D3016-SPE2DB25FBFN0
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Telmisartan-HCTZ 80-25 mg tablets in unit dose packaging (30-count). This competitively awarded, non-set-aside contract carries a ceiling value of $4,574.72 and is structured as a firm fixed-price delivery order with an ultimate completion date of August 13, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Telmisartan-HCTZ 80-25 mg tablets in unit dose packaging (30 count) with a ceiling value of $13,543.19. This is a firm fixed price delivery order with an ultimate completion date of August 21, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Telmisartan-HCTZ 80-25 mg tablets in unit dose packaging (30-count), with a ceiling value of $9,953.41. This delivery order is a firm fixed price contract with no set-aside designation, reflecting competitive award status. The contract is scheduled for ultimate completion by August 1, 2025, with performance taking place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Telmisartan-HCTZ 80-25 mg tablets in unit dose packaging (30-count) with a ceiling value of $5,768.16. This delivery order represents a firm fixed price contract with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for completion on August 6, 2025, and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,151.04 for Telmisartan-HCTZ 80-25 mg tablet unit dose packages (30 count) with an ultimate completion date of August 1, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. The contract covers the supply of this antihypertensive pharmaceutical product to support federal...
- The Defense Logistics Agency awarded a $3,549.93 delivery order to AmerisourceBergen Drug Corp for Telmisartan-HCTZ 80-25 mg tablets (30-count unit dose packaging) on August 19, 2025, with completion scheduled for August 20, 2025. This is a firm fixed price contract with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The delivery location is specified as Conshohocken, PA, where AmerisourceBergen maintains its corporate...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $16,557.69 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide Telmisartan-HCTZ 80-25 mg tablets in 30-count packages. The contract has a performance period through March 18, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp with a potential value of $999,999,999.00 and a performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,362.95 to AmerisourceBergen Drug Corp for the supply of Telmisartan-HCTZ 80-25 mg tablets in unit dose packaging (30-count) with a firm fixed price structure. The contract, awarded on August 21, 2025, with completion targeted for August 22, 2025, represents a competitively awarded, non-set-aside procurement with performance to be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $6,021.48 to AmerisourceBergen Drug Corp for Telmisartan-HCTZ 80-25 mg tablets in unit dose packaging (30-count). This competitively awarded, firm fixed-price delivery order was issued on August 20, 2025, with an ultimate completion date of August 21, 2025. The contract requires performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,773.26 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count). This competitive award utilizes firm fixed price terms with an ultimate completion date of August 19, 2025, and carries no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBFN0Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Telmisartan-HCTZ 80-25 mg tablets in unit dose packages of 30, with a ceiling value of $3,831.03. This delivery order was executed under a firm fixed-price contract type with no set-aside designation, representing a competitively awarded transaction. The order is set for ultimate completion by August 20, 2025, with performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999, which extends through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of medications and medical commodities to support military and veteran healthcare systems. The Telmisartan-HCTZ product represents the company's capability to fulfill federal pharmaceutical procurement across multiple therapeutic domains, with this particular transaction demonstrating the flexibility and efficiency of the larger prime vendor contract vehicle in meeting urgent healthcare supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 8/19/25 |